沛嘉醫療-B(09996.HK)聘請Saibal Kar教授擔任外部顧問
格隆匯9月6日丨沛嘉醫療-B(09996.HK)發佈公吿,公司近期與Saibal Kar, M.D, FACC, FSCAI(“Saibal Kar博士”)訂立顧問協議,聘任他擔任公司的獨家顧問,以為公司的二尖瓣經導管緣對緣修復項目(“Peijia TEER”或“Project Gemini”)的研發提供建議,併為公司提供總體建議。在協議期間及其後一段時間內,他將不會為其他與公司有競爭關係的中國企業提供服務。Peijia TEER是一種旨在為二尖瓣反流患者提供治療的經導管二尖瓣修復療法。該項目正在進行長期的動物試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.